Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Silva Ferraz 2020 Biochem Pharmacol

From Bioblast
Publications in the MiPMap
Silva Ferraz L, Torres da Costa R, Alves da Costa C, Augusto Joรฃo Ribeiro C, Costa Arruda D, Stuchi Maria-Engler S, Rodrigues T (2020) Targeting mitochondria in melanoma: interplay between MAPK signaling pathway and mitochondrial dynamics . Biochem Pharmacol 178:114104.

ยป PMID: 32562785

Ferraz Silva Leticia, Torres da Costa Renata, Alves da Costa Claudia, Augusto Joao Ribeiro Cesar, Costa Arruda Denise, Stuchi Maria-Engler Silvya, Rodrigues Tiago (2020) Biochem Pharmacol

Abstract: Melanoma is a malignant proliferative disease originated in melanocytes, characterized by high metastatic activity and by the activation of oncogenes, such as B-RAF (40-60% of cases). Recent studies have shown that vemurafenib (a MAPK inhibitor) promoted disturbance of mitochondrial bioenergetics, although underlying mechanisms are not fully comprehended. Here we showed that MAPK inhibition by vemurafenib in B-RAFV600E-mutated human melanoma culminated in the inhibition of DRP1 phosphorylation, associated to a large mitochondrial network remodeling to the hyperfused phenotype, and increased oxidative phosphorylation capacity. Such alterations may be associated to melanoma resistance to vemurafenib, since the impairment of oxidative phosphorylation increased the vemurafenib cytotoxicity. These results point to the potential of mitochondrial dynamics as a targetable pathway in melanoma. โ€ข Keywords: B-RAF mutation, MAPK signaling. Melanoma. Mitochondrial Dynamics. Vemurafenib โ€ข Bioblast editor: Plangger M

Labels: MiParea: Respiration, Pharmacology;toxicology  Pathology: Cancer 

Organism: Human  Tissue;cell: Endothelial;epithelial;mesothelial cell  Preparation: Intact cells 

Coupling state: LEAK, ROUTINE, ET 

HRR: Oxygraph-2k